Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study)
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Some patients with depression do not respond to first and second line conventional antidepressants and are therefore characterised as suffering from treatment refractory depression (TRD). On-going psychosocial stress and dysfunction of the hypothalamic-pituitary-adrenal axis are both associated with an attenuated clinical response to antidepressants. Preclinical data shows that co-administration of corticosteroids leads to a reduction in the ability of selective serotonin reuptake inhibitors to increase forebrain 5-hydroxytryptamine, while co-administration of antiglucocorticoids has the opposite effect. A Cochrane review suggests that antiglucocorticoid augmentation of antidepressants may be effective in treating TRD and includes a pilot study of the cortisol synthesis inhibitor, metyrapone. The Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study) is a multicentre randomised placebo controlled trial of metyrapone augmentation of serotonergic antidepressants in a large population of patients with TRD in the UK National Health Service. METHODS/DESIGN: Patients with moderate to severe treatment refractory Major Depression aged 18 to 65 will be randomised to metyrapone 500 mg twice daily or placebo for three weeks, in addition to on-going conventional serotonergic antidepressants. The primary outcome will be improvement in Montgomery-Åsberg Depression Rating Scale score five weeks after randomisation (i.e. two weeks after trial medication discontinuation). Secondary outcomes will include the degree of persistence of treatment effect for up to 6 months, improvements in quality of life and also safety and tolerability of metyrapone. The ADD Study will also include a range of sub-studies investigating the potential mechanism of action of metyrapone. DISCUSSION: Strengths of the ADD study include broad inclusion criteria meaning that the sample will be representative of patients with TRD treated within the UK National Health Service, longer follow up, which to our knowledge is longer than any previous study of antiglucocorticoid treatments in depression, and the range of mechanistic investigations being carried out. The data set acquired will be a rich resource for a range of research questions relating to both refractory depression and the use of antiglucocorticoid treatments. TRIAL REGISTRATION: Current Controlled Trials: ISRCTN45338259; EudraCT Number: 2009-015165-31.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Explaining the gender difference in depressive symptoms.
Nolen-Hoeksema, S., Larson, J., & Grayson, C. (1999) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.77.5.1061 · Cited by 1,543 · cited 1×
“This questionnaire includes the Big Five Inventory 44 personality questionnaire [68], a negative life events questionnaire adapted from the list of Life Threatening Experiences [69], the Social Circumstances Questionnaire, which is an adaptation of the Social Support Questionnaire [70] as used in the NewMood study [67…”
MethodDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 2×
“The degree of treatment refractoriness of patients will be carefully assessed using the MGH-TRD staging scale [64].”
MethodModulating emotional responses: effects of a neocortical network on the limbic system
Hariri, A. R., Bookheimer, S. Y., & Mazziotta, J. C. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00009 · Cited by 1,277 · cited 4×
“5-HT: 5-hydroxytrypatamine; ACTH: Adrenocorticotrophic hormone; ADD: Antiglucocorticoid augmentation of anti-depressants in depression; ANT: Attentional Network Test; BDI: Beck Depressive Inventory; BDNF: Brain derived neurotropic factor; CAR: Cortisol awakening response; CAS: Clinical Anxiety Scale; CRF: Corticotroph…”
BackgroundInfluentialRuhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Two routes to emotional memory: Distinct neural processes for valence and arousal
Kensinger, E. A., & Corkin, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306408101 · Cited by 848 · cited 3×
“5-HT: 5-hydroxytrypatamine; ACTH: Adrenocorticotrophic hormone; ADD: Antiglucocorticoid augmentation of anti-depressants in depression; ANT: Attentional Network Test; BDI: Beck Depressive Inventory; BDNF: Brain derived neurotropic factor; CAR: Cortisol awakening response; CAS: Clinical Anxiety Scale; CRF: Corticotroph…”
BackgroundA systematic review of the mortality of depression
Wulsin, L. R., Vaillant, G. E., & Wells, V. E. (1999) · Psychosomatic Medicine · doi:10.1097/00006842-199901000-00003 · Cited by 703
The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
Heuser, I., Yassouridis, A., & Holsboer, F. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90017-5 · Cited by 662
Emotional bias and inhibitory control processes in mania and depression
MURPHY, F. C., SAHAKIAN, B. J., RUBINSZTEIN, J. S., MICHAEL, A., ROGERS, R. D., ROBBINS, T. W., & PAYKEL, E. S. (1999) · Psychological Medicine · doi:10.1017/s0033291799001233 · Cited by 659
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 1×
“For example personality traits are associated with refractoriness to treatment in patients with depression [83] and the ADD study will characterise personality using the Big Five Inventory 44 personality questionnaire [68].”
Method
Cited by
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citationHPA axis and aging in depression: Systematic review and meta-analysis
Belvederi Murri, M., Pariante, C., Mondelli, V., Masotti, M., Atti, A. R., Mellacqua, Z., Antonioli, M., Ghio, L., Menchetti, M., Zanetidou, S., et al. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.12.004 · Cited by 367
Kvarta, M. D., Bradbrook, K. E., Dantrassy, H. M., Bailey, A. M., & Thompson, S. M. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00359.2015 · Cited by 86
McAllister-Williams, R. H., Anderson, I. M., Finkelmeyer, A., Gallagher, P., Grunze, H. C. R., Haddad, P. M., Hughes, T., Lloyd, A. J., Mamasoula, C., McColl, E., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00436-8 · Cited by 47
Self-citation
Metadata
- Authors
- McAllister-Williams, R. H., Smith, E., Anderson, I. M., Barnes, J., Gallagher, P., Grunze, H. C., Haddad, P. M., House, A. O., Hughes, T., Lloyd, A. J., McColl, E. M., Pearce, S. H., Siddiqi, N., Sinha, B., Speed, C., Steen, I. N., Wainright, J., Watson, S., Winter, F. H., & Ferrier, I. N.
- Venue
- BMC Psychiatry
- Published
- 2013-08-03
- Volume
- 13
- Issue
- 1
- Pages
- 205-205
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2143798755
- Cited by
- 11
- References
- 22
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study). https://app.cochat.ai/papers/10.1186/1471-244x-13-205
- The paper
- McAllister-Williams, R. H., Smith, E., Anderson, I. M., Barnes, J., Gallagher, P., Grunze, H. C., Haddad, P. M., House, A. O., Hughes, T., Lloyd, A. J., McColl, E. M., Pearce, S. H., Siddiqi, N., Sinha, B., Speed, C., Steen, I. N., Wainright, J., Watson, S., Winter, F. H., & Ferrier, I. N. (2013). Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study). BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.